Haemophilia A: Low Dose Emicizumab Effective, Will Reduce Cost by...

Haemophilia A: Low dose emicizumab effective, will reduce cost by...

Last Updated on June 24, 2025 by Team THIP New Delhi, June 24 (IANS) Low dose of emicizumab could be as effective as standard dose against Haemophilia A, according to a study led by the Indian Council of Medical Research (ICMR). Emicizumab is a bispecific monoclonal antibody used to treat hemophilia A — a genetic […] The post Haemophilia A: Low dose emicizumab effective, will reduce cost by over 50 pc, says ICMR study appeared first on THIP Medi…

Denecimig Well-Tolerated in Hemophilia A After Switching from Emicizumab

Parent company Novo Nordisk has announced intentions to submit the treatment for approval later in 2025.

Novo Nordisk presents promising findings for haemophilia treatment - Pharmafile

Novo Nordisk has presented data indicating that a direct switch to Mim8 (denecimig) prophylaxis treatment from emicizumab without a need for a washout period was generally well-tolerated in people with haemophilia A with or without inhibitors. This adds to overall clinical findings for Mim8, based on the company’s FRONTIER trials, accelerating development towards market approval […] The post Novo Nordisk presents promising findings for haemophil…